Amgen Completes Acquisition of KAI Pharmaceuticals

THOUSAND OAKS, Calif.—Amgen  announced on Thursday, July 5, that the acquisition of KAI Pharmaceuticals, a privately held company based in south San Francisco, has come to an end.

The acquisition was initially announced April 10, 2012 and includes KAI's lead product candidate KAI-4169, which is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) who are on dialysis.  KAI has previously reported compelling Phase 2a clinical results for KAI-4169 in this indication. KAI-4169 is administered intravenously at the same time the patient is undergoing dialysis.